Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

The Lancet, Journal Year: 2018, Volume and Issue: 392(10157), P. 1519 - 1529

Published: Oct. 1, 2018

Language: Английский

---

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

The Lancet Diabetes & Endocrinology, Journal Year: 2019, Volume and Issue: 7(10), P. 776 - 785

Published: Aug. 14, 2019

Language: Английский

---

Type 2 diabetes in adolescents and young adults

The Lancet Diabetes & Endocrinology, Journal Year: 2017, Volume and Issue: 6(1), P. 69 - 80

Published: Aug. 26, 2017

Language: Английский

---

Type 2 diabetes mellitus in older adults: clinical considerations and management

Nature Reviews Endocrinology, Journal Year: 2021, Volume and Issue: 17(9), P. 534 - 548

Published: June 25, 2021

Language: Английский

---

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Nature Reviews Nephrology, Journal Year: 2017, Volume and Issue: 13(10), P. 605 - 628

Published: Sept. 4, 2017

Language: Английский

---

Gestational diabetes mellitus - A metabolic and reproductive disorder

Biomedicine & Pharmacotherapy, Journal Year: 2021, Volume and Issue: 143, P. 112183 - 112183

Published: Sept. 21, 2021

Maternal health associated with Gestational Diabetes Mellitus (GDM) has been gaining significant research attention due to its severe risk and adverse effects. GDM is the leading disease in pregnant women. It most common metabolic it can affect up 25% of women during pregnancy. Pregnancy a sensitive period that impacts both their unborn children's long-term health. well-known fact causes mortality worldwide are diabetes mellitus cancer, specifically, at higher developing breast cancer (BC). Women who have equally vulnerable reproductive diseases. Reproductive dysfunctions mainly attributed coexisting polycystic ovarian syndrome (PCOS), obesity, hyperinsulinemia, etc. Moreover, India long recognized as world's diabetic capital, widely acknowledged particularly lactating among affected by diabetes. In India, one-third (33%) had history maternal Nevertheless, latest suggests gestational also factor for cardiometabolic diseases mother offspring. Therefore, 21st century, imposes major challenge healthcare professionals. We intend explore role on female function throughout various stages life perspective changing prognosis, prevalence, prevention GDM.

Language: Английский

---

Peptide therapeutics from venom: Current status and potential

Bioorganic & Medicinal Chemistry, Journal Year: 2017, Volume and Issue: 26(10), P. 2738 - 2758

Published: Sept. 23, 2017

Peptides are recognized as being highly selective, potent and relatively safe potential therapeutics. isolated from the venom of different animals satisfy most these criteria with possible exception safety, but when single compounds used at appropriate concentrations, venom-derived peptides can become useful drugs. Although number that have successfully progressed to clinic is currently limited, prospects for look very optimistic. As proteomic transcriptomic approaches continue identify new sequences, find applications therapeutics, cosmetics insecticides grows accordingly.

Language: Английский

---

Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

Diabetes Care, Journal Year: 2017, Volume and Issue: 40(5), P. 706 - 714

Published: April 12, 2017

Recent randomized trials have compared the newer antidiabetic agents to treatments involving sulfonylureas, drugs associated with increased cardiovascular risks and mortality in some observational studies conflicting results. We reviewed methodology of these by searching MEDLINE from inception December 2015 for all association between sulfonylureas events or mortality. Each study was appraised respect comparator, outcome, design–related sources bias. A meta-regression analysis used evaluate heterogeneity. total 19 were identified, which six had no major design-related biases. Sulfonylureas an risk five (relative 1.16–1.55). Overall, resulted 36 relative as assessed multiple outcomes comparators. Of analyses, metformin comparator 27 (75%) death outcome 24 (67%). The higher 13% when metformin, 20% 7% lowest predicted bias, other than (1.06 [95% CI 0.92–1.23]), whereas highest (1.53 1.43–1.65]). In summary, majority Among important biases, varied significantly type With introduction new drugs, use appropriate design analytical tools will provide their more accurate safety assessment real-world setting.

Language: Английский

---

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

Nephrology Dialysis Transplantation, Journal Year: 2019, Volume and Issue: 34(2), P. 208 - 230

Published: Jan. 25, 2019

Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many these experience progression cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment type 2 DM have emerged, including inhibitors sodium-glucose co-transporter-2 (SGLT-2) glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, were reported to other beneficial effects systems, such as weight loss blood pressure reduction. Most importantly, contrast all studies anti-diabetic agents, series recent randomized, placebo-controlled outcome trials showed that SGLT-2 GLP-1 agonists are able reduce events all-cause mortality, well DM. This document presents detail available evidence on cardioprotective nephroprotective analogues, analyses potential mechanisms involved actions discusses their place CKD

Language: Английский

---

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management

Diabetes Care, Journal Year: 2018, Volume and Issue: 41(8), P. 1543 - 1556

Published: July 11, 2018

The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. With guidelines moving away from a one-size-fits-all approach toward setting patient-centered goals allowing flexibility in choosing second-/third-line drug the growing number U.S. Food Drug Administration–approved agents, keen personalized management T2D has become challenge for health care providers daily practice. Among newer generation classes, sodium–glucose cotransporter inhibitors (SGLT2is), which enhance urinary glucose excretion lower hyperglycemia, have made an imposing entrance armamentarium. Given their unique insulin-independent mode action favorable efficacy–to–adverse event profile given marked benefits on cardiovascular-renal outcome moderate-to-high risk patients, led updates product monographs, role this class multidrug regimes is promising. However, despite many speculations based pharmacokinetic pharmacodynamic properties, physiological reasoning, potential synergism, effects these agents terms pleiotropic efficacy when combined with other classes largely understudied. In perspective, we review currently emerging evidence, discuss prevailing hypotheses, elaborate necessary future studies clarify risks using SGLT2i dual combination metformin triple glucagon-like peptide 1 receptor agonist, dipeptidyl peptidase 4 inhibitor, or agent that recommended by American Diabetes Association European Study (i.e., sulfonylurea, thiazolidinedione, insulin) treat T2D.

Language: Английский

---